Cyclacel Pharmaceuticals, Inc. (CYCC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cyclacel Pharmaceuticals, Inc. (CYCC) with AI Score 43/100 (Weak). Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other proliferative diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Cyclacel Pharmaceuticals, Inc. (CYCC) Healthcare & Pipeline Overview
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development of novel therapies for cancer and proliferative diseases. With a focus on cyclin-dependent kinase (CDK) and polo-like kinase (PLK) inhibitors, the company is currently advancing multiple programs through Phase 1/2 clinical trials, positioning it within the competitive oncology therapeutics landscape.
Investment Thesis
Cyclacel Pharmaceuticals presents a high-risk, high-reward investment opportunity typical of clinical-stage biotech firms. The company's value hinges on the successful progression of its pipeline assets through clinical trials, particularly fadraciclib and CYC140. Positive Phase 1/2 data could serve as a significant catalyst, driving valuation increases. However, the company's negative profit margin of -6714.8% and reliance on future funding introduce substantial financial risk. The low beta of 0.16 suggests lower volatility compared to the overall market, but this does not mitigate the inherent risks of drug development. Investors should closely monitor clinical trial outcomes and cash runway.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01B, reflecting its small-cap status and early stage of development.
- Negative P/E ratio of -0.11, indicating the company is currently not profitable.
- Gross margin of 18.5%, suggesting some efficiency in its research and development processes.
- Profit margin of -6714.8%, highlighting the significant expenses associated with clinical-stage drug development.
- Beta of 0.16, indicating lower volatility compared to the broader market.
Competitors & Peers
Strengths
- Diverse pipeline of clinical-stage drug candidates.
- Targeted therapies with specific mechanisms of action.
- Collaboration with a leading cancer center.
- Experienced management team with expertise in drug development.
Weaknesses
- Limited financial resources and reliance on external funding.
- High risk of clinical trial failures.
- Dependence on partnerships for commercialization.
- Small number of employees.
Catalysts
- Upcoming: Release of Phase 1/2 clinical trial data for fadraciclib in solid tumors.
- Upcoming: Release of Phase 1/2 clinical trial data for CYC140 in advanced leukemias.
- Upcoming: Initiation of new clinical trials for pipeline assets.
- Ongoing: Progression of existing clinical trials through various phases.
- Ongoing: Potential for new strategic partnerships or collaborations.
Risks
- Potential: Failure of clinical trials to meet endpoints.
- Potential: Regulatory delays or rejection of drug candidates.
- Potential: Competition from other companies developing similar therapies.
- Ongoing: Dependence on external funding to support operations.
- Ongoing: Intellectual property challenges and patent disputes.
Growth Opportunities
- Fadraciclib Development: Fadraciclib, a CDK inhibitor, represents a significant growth opportunity for Cyclacel. The drug is currently in Phase 1/2 clinical trials for solid tumors and in combination with venetoclax for relapsed or refractory chronic lymphocytic leukemia. Positive clinical data could lead to further development and potential commercialization, tapping into the multi-billion dollar market for cancer therapeutics. The timeline for potential market entry depends on successful trial outcomes and regulatory approvals.
- CYC140 Development: CYC140, a polo-like kinase inhibitor, is another key growth driver. Currently in Phase 1/2 clinical trials for advanced leukemias and solid tumors, CYC140 targets a different mechanism of action compared to fadraciclib. Success in these trials could expand Cyclacel's pipeline and address a broader range of cancer types. The market for leukemia and solid tumor treatments is substantial, offering significant revenue potential upon successful commercialization.
- Sapacitabine Development: Sapacitabine, an orally available prodrug of CNDAC, is in Phase 1/2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome. This drug offers a convenient oral administration route, potentially improving patient compliance and outcomes. The market for AML and MDS treatments is growing, driven by an aging population and increasing incidence rates. Successful development and commercialization of Sapacitabine could generate significant revenue for Cyclacel.
- Seliciclib Development: Seliciclib, a CDK inhibitor, is currently in Phase 2 investigator-sponsored trials for Cushing's disease and Phase 1/2 trials for advanced rheumatoid arthritis. While not directly related to oncology, successful development in these indications could diversify Cyclacel's pipeline and revenue streams. The market for Cushing's disease and rheumatoid arthritis treatments is substantial, offering potential for growth and expansion beyond cancer therapeutics.
- Strategic Partnerships: Cyclacel's clinical collaboration agreement with the University of Texas MD Anderson Cancer Center represents a strategic growth opportunity. This collaboration allows Cyclacel to leverage the expertise and resources of a leading cancer center to evaluate its medicines in hematological malignancies. Further strategic partnerships with other research institutions or pharmaceutical companies could accelerate the development and commercialization of its pipeline assets.
Opportunities
- Positive clinical trial results leading to regulatory approvals.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of pipeline through in-licensing or acquisition.
- Growing market for cancer therapeutics.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Patent expirations and generic competition.
- Economic downturn affecting funding availability.
Competitive Advantages
- Proprietary drug candidates with unique mechanisms of action.
- Intellectual property protection through patents and exclusivity.
- Clinical data supporting the safety and efficacy of its therapies.
- Strategic collaborations with leading research institutions.
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to treat cancer and other proliferative diseases. The company was founded with the goal of addressing unmet medical needs in oncology through targeted therapies. Cyclacel's pipeline is built upon a deep understanding of cell cycle biology and the mechanisms that drive uncontrolled cell growth in cancer. The company's lead development programs include fadraciclib, a CDK inhibitor in Phase 1/2 trials for solid tumors and in combination with venetoclax for chronic lymphocytic leukemia; CYC140, a PLK inhibitor also in Phase 1/2 trials for advanced leukemias and solid tumors; Sapacitabine, a nucleoside analog in Phase 1/2 trials for acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor in Phase 2 investigator-sponsored trials for Cushing's disease and Phase 1/2 trials for advanced rheumatoid arthritis. Cyclacel has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to evaluate its medicines in hematological malignancies. Headquartered in Berkeley Heights, New Jersey, Cyclacel is focused on advancing its pipeline and bringing new treatment options to patients with cancer.
What They Do
- Develops medicines for the treatment of cancer.
- Focuses on therapies for other proliferative diseases.
- Conducts Phase 1/2 clinical trials for fadraciclib in solid tumors and chronic lymphocytic leukemia.
- Conducts Phase 1/2 clinical trials for CYC140 in advanced leukemias and solid tumors.
- Conducts Phase 1/2 clinical trials for Sapacitabine in acute myeloid leukemia and myelodysplastic syndrome.
- Supports Phase 2 investigator-sponsored trials for seliciclib in Cushing's disease and Phase 1/2 trials for advanced rheumatoid arthritis.
- Collaborates with the University of Texas MD Anderson Cancer Center for clinical evaluations.
Business Model
- Focuses on research and development of novel cancer therapies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties from partnered programs.
- Secures funding through venture capital, public offerings, and grants.
Industry Context
Cyclacel operates within the highly competitive biotechnology industry, specifically targeting oncology. The market for cancer therapeutics is substantial and growing, driven by an aging population and advancements in personalized medicine. The company faces competition from established pharmaceutical giants and other emerging biotech firms, including AMTI, APGN, EPIX, GLS, and IMVIF, all vying for market share with novel therapies. Success in this industry requires significant investment in research and development, navigating complex regulatory pathways, and securing strategic partnerships.
Key Customers
- Patients with cancer and other proliferative diseases.
- Hospitals and oncology clinics.
- Pharmaceutical companies seeking to license or acquire novel therapies.
- Research institutions and universities.
Financials
Chart & Info
Cyclacel Pharmaceuticals, Inc. (CYCC) stock price: Price data unavailable
Latest News
-
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga · Apr 30, 2024
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Sep 8, 2023
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Jan 17, 2023
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · May 26, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYCC.
Price Targets
Wall Street price target analysis for CYCC.
MoonshotScore
What does this score mean?
The MoonshotScore rates CYCC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Leadership: Sing Ee Wong
CEO
Sing Ee Wong serves as the CEO of Cyclacel Pharmaceuticals, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in various biotech companies, focusing on drug development and commercialization. Wong's expertise spans from preclinical research to clinical trials and regulatory affairs. He has a proven track record of driving innovation and building successful teams in the oncology space. His leadership is critical to guiding Cyclacel through its clinical development programs and strategic partnerships.
Track Record: Under Sing Ee Wong's leadership, Cyclacel Pharmaceuticals has focused on advancing its pipeline of clinical-stage drug candidates. Key milestones include initiating and progressing Phase 1/2 clinical trials for fadraciclib and CYC140. Wong has also overseen the company's collaboration with the University of Texas MD Anderson Cancer Center. His strategic decisions have been instrumental in securing funding and partnerships to support the company's research and development efforts.
CYCC Healthcare Stock FAQ
What does Cyclacel Pharmaceuticals, Inc. do?
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer and other proliferative diseases. The company's pipeline includes several drug candidates in Phase 1/2 clinical trials, targeting various forms of leukemia, solid tumors, and other hematological malignancies. Cyclacel aims to address unmet medical needs in oncology by developing targeted therapies that disrupt the cell cycle and inhibit uncontrolled cell growth. Their business model involves research and development, clinical trials, and potential out-licensing or partnering for commercialization.
What do analysts say about CYCC stock?
As of March 16, 2026, there is no readily available analyst consensus on Cyclacel Pharmaceuticals (CYCC) due to its small market capitalization and early stage of development. Key valuation metrics such as P/E ratio are not meaningful due to the company's lack of profitability. Growth considerations revolve around the successful progression of its pipeline assets through clinical trials. Investors should conduct their own due diligence and carefully evaluate the risks and potential rewards associated with investing in CYCC, considering its speculative nature.
What are the main risks for CYCC?
The main risks for Cyclacel Pharmaceuticals (CYCC) are typical of clinical-stage biotech companies. These include the risk of clinical trial failures, regulatory hurdles, competition from other companies, and dependence on external funding. Specifically, the failure of fadraciclib or CYC140 to demonstrate efficacy in clinical trials would significantly impact the company's value. Additionally, delays in regulatory approvals or challenges to its intellectual property could negatively affect its prospects. The company's limited financial resources also pose a risk, as it relies on securing additional funding to continue its operations.
What is Cyclacel Pharmaceuticals, Inc.'s drug pipeline status?
Cyclacel Pharmaceuticals, Inc.'s pipeline includes fadraciclib, a CDK inhibitor in Phase 1/2 trials for solid tumors and chronic lymphocytic leukemia; CYC140, a PLK inhibitor in Phase 1/2 trials for advanced leukemias and solid tumors; Sapacitabine, a nucleoside analog in Phase 1/2 trials for acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor in Phase 2 investigator-sponsored trials for Cushing's disease and Phase 1/2 trials for advanced rheumatoid arthritis. Upcoming catalysts include data releases from ongoing Phase 1/2 trials.
How does Cyclacel Pharmaceuticals, Inc. manage its intellectual property?
Cyclacel Pharmaceuticals, Inc. protects its intellectual property through a combination of patents, trade secrets, and other proprietary rights. The company seeks patent protection for its drug candidates, formulations, and methods of use. They also employ strategies to maintain the confidentiality of their research and development activities. However, the biotechnology industry is characterized by intense competition and frequent patent disputes, so Cyclacel faces the ongoing risk of challenges to its intellectual property rights.
What are the key factors to evaluate for CYCC?
Cyclacel Pharmaceuticals, Inc. (CYCC) currently holds an AI score of 43/100, indicating low score. Key strength: Diverse pipeline of clinical-stage drug candidates.. Primary risk to monitor: Potential: Failure of clinical trials to meet endpoints.. This is not financial advice.
How frequently does CYCC data refresh on this page?
CYCC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CYCC's recent stock price performance?
Recent price movement in Cyclacel Pharmaceuticals, Inc. (CYCC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse pipeline of clinical-stage drug candidates.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.